Genetic Alterations in Members of the Proteasome 26S Subunit, AAA-ATPase (PSMC) Gene Family in the Light of Proteasome Inhibitor Resistance in Multiple Myeloma

Simple Summary In comparison to other neoplasias, Multiple Myeloma is extremely sensitive to changes in protein homeostasis. Therefore, proteasome inhibitors are highly efficient and widely used for this disease. Genetic alterations of the PSMC genes, such as the ones shown in this manuscript, affect this Multiple Myeloma vulnerability and, therefore, play a key role in the physiopathogenesis and resistance to proteasome inhibitors. By different modes of action, those alterations are likely to increase the proteolytic capacity of cancer cells. Even though they occur in low frequencies, they can serve as biomarkers to predict and monitor a patient's response to proteasome inhibitors over time and might be useful to guide therapy. For the treatment of Multiple Myeloma, proteasome inhibitors are highly efficient and widely used, but resistance is a major obstacle to successful therapy. Several underlying mechanisms have been proposed but were only reported for a minority of resistant patients. The proteasome is a large and complex machinery. Here, we focus on the AAA ATPases of the 19S proteasome regulator (PSMC1-6) and their implication in PI resistance. As an example of cancer evolution and the acquisition of resistance, we conducted an in-depth analysis of an index patient by applying FISH, WES, and immunoglobulin-rearrangement sequencing in serial samples, starting from MGUS to newly diagnosed Multiple Myeloma to a PI-resistant relapse. The WES analysis uncovered an acquired PSMC2 Y429S mutation at the relapse after intensive bortezomib-containing therapy, which was functionally confirmed to mediate PI resistance. A meta-analysis comprising 1499 newly diagnosed and 447 progressed patients revealed a total of 36 SNVs over all six PSMC genes that were structurally accumulated in regulatory sites for activity such as the ADP/ATP binding pocket. Other alterations impact the interaction between different PSMC subunits or the intrinsic conformation of an individual subunit, consequently affecting the folding and function of the complex. Interestingly, several mutations were clustered in the central channel of the ATPase ring, where the unfolded substrates enter the 20S core. Our results indicate that PSMC SNVs play a role in PI resistance in MM.

Automated summary

Compared to other neoplasias, Multiple Myeloma is highly responsive to proteasome inhibitors due to its sensitivity to changes in protein homeostasis. Genetic alterations of PSMC genes affect the susceptibility of Multiple Myeloma to proteasome inhibitors, playing a significant role in disease development and resistance. These alterations can serve as biomarkers to predict and monitor patient response, guiding treatment decisions.